Product Description: Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Parrondo RD, et, al. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020 Dec;191(5):673-681.